Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 13c, Beats on Revenues; Offers FY17 OpEx Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Syndax Pharmaceuticals (SNDX) PT Lowered to $20 at Citi; Reiterates Buy
August 11, 2017 8:56 AM EDTCiti lowered its price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $20.00 (from $24.00) while maintaining a Buy rating. Citi... More
Syndax Pharmaceuticals (SNDX) PT Lowered to $22 at Nomura/Instinet on Mixed 2Q Results
August 11, 2017 8:54 AM EDTNomura/Instinet lowered its price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $22.00 (from $27.00) while maintaining a Buy rating, following the company's second quarter earnings report.
Analyst Christopher Marai notes the company delivered second quarter earnings per share below expectations, despite revenues in-line with estimates,... More
